<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">29297305</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2105</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>Suppl 16</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>BMC bioinformatics</Title><ISOAbbreviation>BMC Bioinformatics</ISOAbbreviation></Journal><ArticleTitle>Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection.</ArticleTitle><Pagination><StartPage>548</StartPage><MedlinePgn>548</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">548</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12859-017-1957-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Viruses of the flaviviridae family are responsible for some of the major infectious viral diseases around the world and there is an urgent need for drug development for these diseases. Most of the virtual screening methods in flaviviral drug discovery suffer from a low hit rate, strain-specific efficacy differences, and susceptibility to resistance. It is because they often fail to capture the key pharmacological features of the target active site critical for protein function inhibition. So in our current work,&#xa0;for the flaviviral NS3 protease, we summarized the pharmacophore features at the protease active site as anchors (subsite-moiety interactions).</AbstractText><AbstractText Label="RESULTS">For each of the four flaviviral NS3 proteases (i.e., HCV, DENV, WNV, and JEV), the anchors were&#xa0;obtained and summarized into 'Pharmacophore anchor (PA) models'. To capture the conserved pharmacophore anchors across these proteases, were merged the four PA models. We identified five consensus core anchors (CEH1, CH3, CH7, CV1, CV3) in all PA models, represented as the "Core pharmacophore anchor (CPA) model" and also identified specific anchors unique to the PA models. Our PA/CPA models complied with 89 known NS3 protease inhibitors. Furthermore, we proposed an integrated anchor-based screening method using the anchors from our models for discovering inhibitors. This method was applied on the DENV NS3 protease to screen FDA drugs discovering boceprevir, telaprevir and asunaprevir as promising anti-DENV candidates. Experimental testing against DV2-NGC virus by in-vitro plaque assays showed that asunaprevir and telaprevir inhibited viral replication with EC<sub>50</sub> values of 10.4&#xa0;&#x3bc;M &amp; 24.5&#xa0;&#x3bc;M respectively. The structure-anchor-activity relationships (SAAR) showed that our PA/CPA model anchors explained the observed in-vitro activities of the candidates. Also, we observed that the CEH1 anchor engagement was critical for the activities of telaprevir and asunaprevir while the extent of inhibitor anchor occupation guided their efficacies.</AbstractText><AbstractText Label="CONCLUSION">These results validate our NS3 protease PA/CPA models, anchors and the integrated anchor-based screening method to be useful in inhibitor discovery and lead optimization, thus accelerating flaviviral drug discovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>TIGP-Bioinformatics, Institute of Information Science, Academia Sinica, Taipei, 115, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Structural Biology and Bioinformatics, National Tsing Hua University, Hsinchu, 30013, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Mei-Ling</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, 35053, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Bioinformatics and Systems Biology, National Chiao Tung University, Hsinchu, 30050, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wen-Yu</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Graduate Institute of Immunology, National Taiwan University- College of Medicine, Taipei, 10617, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Betty-Wu</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Graduate Institute of Immunology, National Taiwan University- College of Medicine, Taipei, 10617, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Guann-Yi</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, 35053, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jinn-Moon</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>TIGP-Bioinformatics, Institute of Information Science, Academia Sinica, Taipei, 115, Taiwan. moon@faculty.nctu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Bioinformatics and Systems Biology, National Chiao Tung University, Hsinchu, 30050, Taiwan. moon@faculty.nctu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, 30050, Taiwan. moon@faculty.nctu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Bioinformatics</MedlineTA><NlmUniqueID>100965194</NlmUniqueID><ISSNLinking>1471-2105</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005416" MajorTopicYN="N">Flavivirus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Core and specific anchors</Keyword><Keyword MajorTopicYN="N">DENV NS3 protease</Keyword><Keyword MajorTopicYN="N">Flaviviral NS3 proteases</Keyword><Keyword MajorTopicYN="N">Integrated anchor-based virtual screening</Keyword><Keyword MajorTopicYN="N">Pharmacophore anchor models</Keyword></KeywordList><CoiStatement>COMPETING INTEREST: The authors declare that they have no competing interests. ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable ABOUT THIS SUPPLEMENT: This article has been published as part of <i>BMC Bioinformatics</i> Volume 18 Supplement 16, 2017: 16th International Conference on Bioinformatics (InCoB 2017): Bioinformatics. The full contents of the supplement are available online at https://bmcbioinformatics.biomedcentral.com/articles/supplements/volume-18-supplement-16. CONSENT FOR PUBLICATION: Not applicable PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29297305</ArticleId><ArticleId IdType="pmc">PMC5751397</ArticleId><ArticleId IdType="doi">10.1186/s12859-017-1957-5</ArticleId><ArticleId IdType="pii">10.1186/s12859-017-1957-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talwani R, Gilliam BL, Rizza SA, Nehra V, Temesgen Z. Current status of treatment for chronic hepatitis C virus infection. Drugs Today (Barc) 2012;48(3):219&#x2013;231. doi: 10.1358/dot.2012.48.3.1740457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/dot.2012.48.3.1740457</ArticleId><ArticleId IdType="pubmed">22462041</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X. Direct anti-HCV agents. Acta Pharm Sin B. 2016;6(1):26&#x2013;31. doi: 10.1016/j.apsb.2015.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2015.09.008</ArticleId><ArticleId IdType="pmc">PMC4724659</ArticleId><ArticleId IdType="pubmed">26904396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferenci P. Viral hepatitis: cure of chronic hepatitis C--required length of follow-up? Nat Rev Gastroenterol Hepatol. 2015;12(1):10&#x2013;11. doi: 10.1038/nrgastro.2014.198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.198</ArticleId><ArticleId IdType="pubmed">25421584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: treatment of difficult to treat patients. World J Hepatol. 2015;7(15):1953&#x2013;1963. doi: 10.4254/wjh.v7.i15.1953.</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/wjh.v7.i15.1953</ArticleId><ArticleId IdType="pmc">PMC4517154</ArticleId><ArticleId IdType="pubmed">26244069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjit S, Kissoon N. Dengue hemorrhagic fever and shock syndromes. Pediatr Crit Care Med. 2011;12(1):90&#x2013;100. doi: 10.1097/PCC.0b013e3181e911a7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181e911a7</ArticleId><ArticleId IdType="pubmed">20639791</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504&#x2013;507. doi: 10.1038/nature12060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinschmidt-DeMasters BK, Beckham JD. West Nile virus encephalitis 16 years later. Brain Pathol. 2015;25(5):625&#x2013;633. doi: 10.1111/bpa.12280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12280</ArticleId><ArticleId IdType="pubmed">26276026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa T, Konishi E. Potential chemotherapeutic targets for Japanese encephalitis: current status of antiviral drug development and future challenges. Expert Opin Ther Targets. 2015;19(10):1379&#x2013;1395. doi: 10.1517/14728222.2015.1065817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.2015.1065817</ArticleId><ArticleId IdType="pubmed">26156208</ArticleId></ArticleIdList></Reference><Reference><Citation>Knox J, Cowan RU, Doyle JS, Ligtermoet MK, Archer JS, Burrow JN, Tong SY, Currie BJ, Mackenzie JS, Smith DW, et al. Murray Valley encephalitis: a review of clinical features, diagnosis and treatment. Med J Aust. 2012;196(5):322&#x2013;326. doi: 10.5694/mja11.11026.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja11.11026</ArticleId><ArticleId IdType="pubmed">22432670</ArticleId></ArticleIdList></Reference><Reference><Citation>Beasley DW, McAuley AJ, Bente DA. Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy. Antivir Res. 2015;115:48&#x2013;70. doi: 10.1016/j.antiviral.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.12.010</ArticleId><ArticleId IdType="pubmed">25545072</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchardt RA. Zika virus: a rapidly emerging infectious disease. JAAPA. 2016;29(4):48&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">26953673</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabel GJ, Zerhouni EA. Once and future epidemics: Zika virus emerging. Sci Transl Med. 2016;8(330):330ed332. doi: 10.1126/scitranslmed.aaf4548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf4548</ArticleId><ArticleId IdType="pubmed">27089202</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong CW. Zika virus: an emerging infectious threat. Intern Med J. 2016;46(5):525&#x2013;530. doi: 10.1111/imj.13059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.13059</ArticleId><ArticleId IdType="pubmed">27170237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp. 2006;277:3&#x2013;16. doi: 10.1002/0470058005.ch2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0470058005.ch2</ArticleId><ArticleId IdType="pubmed">17319151</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedjadi T, El-Kafrawy S, Sohrab SS, Despres P, Damanhouri G, Azhar E. Tackling dengue fever: current status and challenges. Virol J. 2015;12:212. doi: 10.1186/s12985-015-0444-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-015-0444-8</ArticleId><ArticleId IdType="pmc">PMC4673751</ArticleId><ArticleId IdType="pubmed">26645066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, Yokokawa F, Nilar S, Smith P, Beer D, et al. Ten years of dengue drug discovery: progress and prospects. Antivir Res. 2013;100(2):500&#x2013;519. doi: 10.1016/j.antiviral.2013.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.09.013</ArticleId><ArticleId IdType="pubmed">24076358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, Cook S, Coutard B, Decroly E, de Lamballerie X, Gould EA, et al. Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antivir Res. 2010;87(2):125&#x2013;148. doi: 10.1016/j.antiviral.2009.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.11.009</ArticleId><ArticleId IdType="pmc">PMC3918146</ArticleId><ArticleId IdType="pubmed">19945487</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecher M, Zhang J, Li H. The flavivirus protease as a target for drug discovery. Virol Sin. 2013;28(6):326&#x2013;336. doi: 10.1007/s12250-013-3390-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-013-3390-x</ArticleId><ArticleId IdType="pmc">PMC3927373</ArticleId><ArticleId IdType="pubmed">24242363</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D, Vasudevan SG, Lescar J. The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. Antivir Res. 2015;118:148&#x2013;158. doi: 10.1016/j.antiviral.2015.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.03.014</ArticleId><ArticleId IdType="pubmed">25842996</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampath A, Padmanabhan R. Molecular targets for flavivirus drug discovery. Antivir Res. 2009;81(1):6&#x2013;15. doi: 10.1016/j.antiviral.2008.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.08.004</ArticleId><ArticleId IdType="pmc">PMC2647018</ArticleId><ArticleId IdType="pubmed">18796313</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiss BJ, Stahla H, Hannah AM, Gari AM, Keenan SM. Focus on flaviviruses: current and future drug targets. Future Med Chem. 2009;1(2):327&#x2013;344. doi: 10.4155/fmc.09.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc.09.27</ArticleId><ArticleId IdType="pmc">PMC2822355</ArticleId><ArticleId IdType="pubmed">20165556</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiryaev SA, Strongin AY. Structural and functional parameters of the flaviviral protease: a promising antiviral drug target. Future Virol. 2010;5(5):593&#x2013;606. doi: 10.2217/fvl.10.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl.10.39</ArticleId><ArticleId IdType="pmc">PMC2976050</ArticleId><ArticleId IdType="pubmed">21076642</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulsen A, Kang C, Keller TH. Drug design for flavivirus proteases: what are we missing? Curr Pharm Des. 2014;20(21):3422&#x2013;3427. doi: 10.2174/13816128113199990633.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/13816128113199990633</ArticleId><ArticleId IdType="pubmed">24001226</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson SM, Malmstrom RD, Russo A, Mueller N, Pang YP, Watowich SJ. Structure-based discovery of dengue virus protease inhibitors. Antivir Res. 2009;82(3):110&#x2013;114. doi: 10.1016/j.antiviral.2009.02.190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.02.190</ArticleId><ArticleId IdType="pmc">PMC2680748</ArticleId><ArticleId IdType="pubmed">19428601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabarcas-Montalvo M, Maldonado-Rojas W, Montes-Grajales D, Bertel-Sevilla A, Wagner-Dobler I, Sztajer H, Reck M, Flechas-Alarcon M, Ocazionez R, Olivero-Verbel J. Discovery of antiviral molecules for dengue: in silico search and biological evaluation. Eur J Med Chem. 2016;110:87&#x2013;97. doi: 10.1016/j.ejmech.2015.12.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2015.12.030</ArticleId><ArticleId IdType="pubmed">26807547</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente CR, Herbinger KH, Froschl G, Malta Romano C, de Souza Areias Cabidelle A, Cerutti Junior C. Serotype influences on dengue severity: a cross-sectional study on 485 confirmed dengue cases in Vitoria, Brazil. BMC Infect Dis. 2016;16:320. doi: 10.1186/s12879-016-1668-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1668-y</ArticleId><ArticleId IdType="pmc">PMC4938938</ArticleId><ArticleId IdType="pubmed">27393011</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano KP, Ali A, Royer WE, Schiffer CA. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A. 2010;107(49):20986&#x2013;20991. doi: 10.1073/pnas.1006370107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006370107</ArticleId><ArticleId IdType="pmc">PMC3000259</ArticleId><ArticleId IdType="pubmed">21084633</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YF, Hsu KC, Lin SR, Wang WC, Huang YC, Yang JM. SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moieties. Nucleic Acids Res. 2010;38(Web Server issue):W424&#x2013;W430. doi: 10.1093/nar/gkq480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq480</ArticleId><ArticleId IdType="pmc">PMC2896162</ArticleId><ArticleId IdType="pubmed">20519201</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JM, Chen CC. GEMDOCK: a generic evolutionary method for molecular docking. Proteins. 2004;55(2):288&#x2013;304. doi: 10.1002/prot.20035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.20035</ArticleId><ArticleId IdType="pubmed">15048822</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu KC, Chen YF, Lin SR, Yang JM. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinformatics. 2011;12(Suppl 1):S33. doi: 10.1186/1471-2105-12-S1-S33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-S1-S33</ArticleId><ArticleId IdType="pmc">PMC3044289</ArticleId><ArticleId IdType="pubmed">21342564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz IC, Marcotrigiano J, Dentzer TG, Rice CM. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature. 2006;442(7104):831&#x2013;835. doi: 10.1038/nature04975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04975</ArticleId><ArticleId IdType="pubmed">16862121</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble CG, Seh CC, Chao AT, Shi PY. Ligand-bound structures of the dengue virus protease reveal the active conformation. J Virol. 2012;86(1):438&#x2013;446. doi: 10.1128/JVI.06225-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06225-11</ArticleId><ArticleId IdType="pmc">PMC3255909</ArticleId><ArticleId IdType="pubmed">22031935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu KC, Cheng WC, Chen YF, Wang HJ, Li LT, Wang WC, Yang JM. Core site-moiety maps reveal inhibitors and binding mechanisms of orthologous proteins by screening compound libraries. PLoS One. 2012;7(2):e32142. doi: 10.1371/journal.pone.0032142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032142</ArticleId><ArticleId IdType="pmc">PMC3290551</ArticleId><ArticleId IdType="pubmed">22393385</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu KC, Cheng WC, Chen YF, Wang WC, Yang JM. Pathway-based screening strategy for multitarget inhibitors of diverse proteins in metabolic pathways. PLoS Comput Biol. 2013;9(7):e1003127. doi: 10.1371/journal.pcbi.1003127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003127</ArticleId><ArticleId IdType="pmc">PMC3701698</ArticleId><ArticleId IdType="pubmed">23861662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascione A. Boceprevir in chronic hepatitis C infection: a perspective review. Ther Adv Chronic Dis. 2012;3(3):113&#x2013;121. doi: 10.1177/2040622312441496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040622312441496</ArticleId><ArticleId IdType="pmc">PMC3513904</ArticleId><ArticleId IdType="pubmed">23251772</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesudian AB, Jacobson IM. Telaprevir for chronic hepatitis C virus infection. Clin Liver Dis. 2013;17(1):47&#x2013;62. doi: 10.1016/j.cld.2012.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cld.2012.09.010</ArticleId><ArticleId IdType="pubmed">23177282</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014;10:493&#x2013;504. doi: 10.2147/TCRM.S66731.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S66731</ArticleId><ArticleId IdType="pmc">PMC4079632</ArticleId><ArticleId IdType="pubmed">25061308</ArticleId></ArticleIdList></Reference><Reference><Citation>Soumana DI, Ali A, Schiffer CA. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem Biol. 2014;9(11):2485&#x2013;2490. doi: 10.1021/cb5006118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cb5006118</ArticleId><ArticleId IdType="pmc">PMC4245159</ArticleId><ArticleId IdType="pubmed">25243902</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG, Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol. 2006;13(4):372&#x2013;373. doi: 10.1038/nsmb1073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb1073</ArticleId><ArticleId IdType="pubmed">16532006</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinert T, Olieric V, Waltersperger S, Panepucci E, Chen L, Zhang H, Zhou D, Rose J, Ebihara A, Kuramitsu S, et al. Fast native-SAD phasing for routine macromolecular structure determination. Nat Methods. 2015;12(2):131&#x2013;133. doi: 10.1038/nmeth.3211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3211</ArticleId><ArticleId IdType="pubmed">25506719</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model. 2012;52(7):1757&#x2013;1768. doi: 10.1021/ci3001277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci3001277</ArticleId><ArticleId IdType="pmc">PMC3402020</ArticleId><ArticleId IdType="pubmed">22587354</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007;35(Database issue):D198&#x2013;D201. doi: 10.1093/nar/gkl999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkl999</ArticleId><ArticleId IdType="pmc">PMC1751547</ArticleId><ArticleId IdType="pubmed">17145705</ArticleId></ArticleIdList></Reference><Reference><Citation>Shindyalov IN, Bourne PE. Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng. 1998;11(9):739&#x2013;747. doi: 10.1093/protein/11.9.739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/11.9.739</ArticleId><ArticleId IdType="pubmed">9796821</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>